NEWORMICS
Newormics is a developer of the first high-throughput, high-content drug screening platforms for use with in vivo small animal models as well as in vitro 3D tissue constructs. The company provides proprietary microfluidics-based platforms to advance early stage drug discovery and toxicity studies for faster and better drug development with cost-effective solutions.
NEWORMICS
Industry:
Biotechnology Medical Pharmaceutical
Address:
Austin, Texas, United States
Country:
United States
Website Url:
http://www.newormics.com
Total Employee:
1+
Status:
Active
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Investors List
MassChallenge
MassChallenge investment in Non Equity Assistance - Newormics
Official Site Inspections
http://www.newormics.com
- Host name: 192.0.78.219
- IP address: 192.0.78.219
- Location: San Francisco United States
- Latitude: 37.7506
- Longitude: -122.4121
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94110
More informations about "Newormics"
Newormics - Crunchbase Company Profile & Funding
Newormics is a developer of the first high-throughput, high-content drug screening platforms for use with in vivo small animal models as well as in vitro 3D tissue constructs. The company …See details»
About Us - vivoVerse
VivoVerse, LLC., formerly operating as Newormics LLC, develops and manufactures advanced microfluidics, automation, and AI/ML technologies to rapidly and ethically test toxicology/safety profiles of chemicals using C. …See details»
Newormics - Overview, News & Similar companies | ZoomInfo.com
Newormics is a developer of the first high-throughput, high-content screening platforms for use with in vivo small animal models as well as in vitro 3D tissue organoids. The company …See details»
vivoVerse | Accelerating in vivo screening - vivoVerse
Our innovative high-throughput platform integrated with AI-enabled data analytics provides cost effective and rapid testing. Protect public health with early identification of toxic chemicals. Help industries reduce animal use and meet …See details»
Newormics - Products, Competitors, Financials, Employees, …
VivoVerse, formerly known as Newormics, focuses on accelerating in vivo screening within the biotechnology sector. Use the CB Insights Platform to explore Newormics's full profile.See details»
Newormics, LLC Company Profile | Austin, TX - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Newormics, LLC of Austin, TX. Get the latest business insights from Dun & Bradstreet.See details»
Newormics, LLC - VentureRadar
To fulfill the unmet need of HCS using humanized animal models, Newormics’ first product, a microfluidic-based platform, enables fast automated phenotyping of humanized C. elegans …See details»
Newormics - Contacts, Employees, Board Members, Advisors
Co-Founder, Principal Investigator, Dir. Of Manufacturing. Newormics is a developer of the first high-throughput, high-content drug screening platforms.See details»
Newormics - Crunchbase
Newormics is a developer of the first high-throughput, high-content drug screening platforms.See details»
Welcome to Newormics: High-throughput and high-content …
Oct 29, 2018 · Newormics is spinoff from the Femtosecond Laboratory in Dr. Ben-Yakar’s Group at the University of Texas at Austin. Newormics is a developer of the first high-throughput, high …See details»
vivoVerse moves into new HQ
May 5, 2021 · vivoVerse (formerly operating as Newormics) has expanded its base of operations into a customized, newly refurbished space in Austin, Texas. The new headquarters comprises over 2400 square-foot of laboratory, office, …See details»
MicroTAS 2020 | October 4-9, 2020 | Online - MicroTAS Conferences
Www.newormics.com Newormics develops high-throughput, high-content, microfluidics-based imaging systems for toxicology screens and disease modeling, using small model organisms …See details»
Omics Solutions for Precision Medicine | Newomics
Nov 12, 2024 · Newomics products guarantee high sensitivity, high throughput, robustness, and plug-and-play design. High-performance devices for LC-MS.See details»
Newormics Austin Office: Careers, Perks + Culture | Built In Austin
Newormics offers high-throughput and high-content screening devices for small model animals and 3D tissue organoids. The pharma, cosmetic, and AgChem industries are shifting to …See details»
vivoVerse awarded SBIR Phase II grant from the NIMH
Jul 8, 2020 · vivoVerse (formerly operating as Newormics) is excited to announce it has been awarded a $2.25M Phase II SBIR grant from the National Institutes of Health/National Institute …See details»
UT Spinout Newormics to Test HIV-AIDS Treatments Using Novel …
Jul 30, 2020 · Newormics, a drug screening spinout created at The University of Texas Austin's Cockrell School of Engineering, received a National Institutes of Health Small Business …See details»
Newormics - Funding, Financials, Valuation & Investors - Crunchbase
Feb 21, 2018 · Newormics is a developer of the first high-throughput, high-content drug screening platforms.See details»
Newomics Company Profile 2024: Valuation, Funding & Investors
Developer of a biotechnology platform designed to create multi-omics diagnostic assays for diabetes, Alzheimer's, and other diseases.See details»
Newormics co-founder, Adela Ben-Yakar, featured by the …
Sep 20, 2019 · ‘Mechanical engineer Adela Ben-Yakar, at the University of Texas at Austin, collaborated with stem cell biologist Joshua Brickman, from the University of Copenhagen in …See details»
Jay Bhattacharya picked by Trump to lead NIH : Shots - NPR
1 day ago · Dr. Jay Bhattacharya, a Stanford health researcher, is in line to lead the National Institutes of Health. Early in the pandemic he argued against lockdowns and focusing on …See details»